KRAS and cancer: We also detected that enhanced effects from AMG510 for cancer cell killing result from either IN10018 or YAP1 siRNA, further supporting that the aberrantly activated FAK–YAP signaling contributes to the compromised efficacy of KRAS G12C inhibitors.